But it is important not to confuse domestic capacity with supply resilience. Geography Is Only One Layer of Concentration RiskThe current debate often frames pharmaceutical supply chains as a choice between offshore dependence and domestic self-sufficiency. The commercial objective must be to identify vulnerability while the supply chain still appears to be functioning normally. FDA continues to identify manufacturing quality issues as the most common reason for drug shortages . Quality, regulatory, supply chain, finance and commercial teams need predetermined decision rights.